Boston Scientific, Inc. (BSX) appears in good shape, with its shares rallying 4.6% since the fourth-quarter earnings release. The company is gaining from strong worldwide demand for its GI and pulmonary treatment options. The traction in Europe for its next-generation WATCHMAN FLX and a contribution from accretive acquisitions are important growth drivers. The Zacks Rank #2 (Buy) stock has moved up 4.6% since the last earnings release compared with the industry’s rise of 1%. The Medical sector has increased ...